Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette Syndrome
(Stockholm, April 1, 2023) Asarina Pharma today releases results from its Phase IIa study of the endogenous neurosteroid Sepranolone for the treatment of Tourette Syndrome.… Read More »Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette Syndrome